Best Drug for Treatment Rheumatoid Arthritis Review of Effectiveness

Research

Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient information

BMJ 2020; 370 doi: https://doi.org/x.1136/bmj.m2288 (Published 07 July 2020) Cite this as: BMJ 2020;370:m2288

Linked Stance

Lessons from a network meta-assay of biologics in rheumatoid arthritis

Kirsten Janke , researcheri,
Katharina Biester , senior researcher1,
Dietmar Krause , rheumatologist3,
Bernd Richter , analogous editor4,
Christoph Schürmann , statistician2,
Katharina Hirsch , statistician2,
Helmut Hörn , researcher1,
Michaela Florina Kerekes , information manager1,
Petra Kohlepp , data managerane,
Beate Wieseler , head of department1

¹Drug Assessment Section, Institute for Quality and Efficiency in Health Care, Im Mediapark 8, Cologne 50670, Germany
²Medical Biometry Department, Institute for Quality and Efficiency in Health Care, Cologne, Germany
³Rheumatology Practice Gladbeck, Gladbeck, Federal republic of germany
⁴Cochrane Metabolic and Endocrine Disorders Group, Institute of Full general Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Federal republic of germany

Correspondence to: B Wieseler beate.wieseler{at}iqwig.de

Accustomed xxx April 2020

Abstract

Objective To assess the comparative effectiveness of biological medicines in rheumatoid arthritis in sufficiently similar patient populations, based on the electric current definitions of key outcomes.

Design Systematic review and network meta-analysis including aggregate results from reanalysed private patient data.

Information sources Clinical study reports and amass results from reanalyses of individual patient data on key outcomes for rheumatoid arthritis provided by study sponsors for studies conducted upwards to 2017, and several databases and registries from inception upwardly to February 2017.

Eligibility criteria for selecting studies Randomised controlled trials investigating patient relevant outcomes in adults with rheumatoid arthritis treated with biological medicines in combination with methotrexate afterward methotrexate failure for at least 24 weeks.

Results 45 eligible trials were identified. Combining data from clinical written report reports and aggregate results from reanalyses of individual patient data allowed all-encompassing analyses yielding sufficiently similar populations and homogeneous study results for network meta-analyses, including up to 35 studies on eight biological medicines combined with methotrexate. These analyses showed few statistically significant differences between the combination treatments. For example, anakinra showed less benefit than almost all the other vii biological medicines regarding clinical remission or low disease activity (clinical disease activeness index ≤two.8 or ≤ten, respectively) and certolizumab pegol showed more harm than the other seven biological medicines regarding serious adverse events or infections. Some outcomes had very broad 95% confidence intervals, potentially implying unidentified differences between the eight biological medicines, but wide 95% conviction intervals were less prominent for low disease action, serious adverse events, and infections. Owing to a lack of caput-to-head trials, results were mainly based on indirect comparisons with a limited number of studies, and recently approved Janus kinase inhibitors could non be included.

Conclusions For patients with rheumatoid arthritis after methotrexate failure, just minor differences in benefits and harms were seen betwixt biological medicines in combination with methotrexate. All the same, the analysis was hampered by a lack of long term directly comparisons. The substantial information gain accomplished by the reanalysis of individual patient data calls for the routine availability of individual patient data.

Introduction

Rheumatoid arthritis is 1 of the nearly mutual chronic inflammatory diseases. Joint inflammation tin can lead to pain, stiffness, swelling, structural harm, and impaired role.123 Ultimately, rheumatoid arthritis tin crusade progressive inability and premature expiry.4567

Treatment for the rheumatoid arthritis primarily aims to reduce illness activity to a level where patients are complimentary of signs and symptoms of inflammatory activity (that is, clinical remission).viii Depression disease activity can too be an acceptable treatment goal, especially for patients with previous treatment failure.nine The most recent and stringent definitions for clinical remission and low disease action have been suggested past the American College of Rheumatology (ACR) and the European League Confronting Rheumatism (EULAR).10

Current options for rheumatoid arthritis include disease modifying antirheumatic drugs (DMARDs), which can be combined with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.3911 DMARDs are divided into conventional synthetic DMARDs (eg, methotrexate), targeted synthetic DMARDs (Janus kinase inhibitors), and biological DMARDs (biological medicines or bDMARD).12 Although a wide range of biological medicines is bachelor, their comparative effectiveness is still under discussion.

This systematic review of randomised controlled trials aimed to compare the benefits and harms of biological medicines in combination with methotrexate in patients with rheumatoid arthritis later methotrexate failure. Given the many biological medicines available, nosotros used a network meta-analysis to compare several different treatments. An important prerequisite for such an assay is the similarity of the studies included. We obtained like patient populations by using aggregate results from systematic reanalyses of individual patient data performed by report sponsors for those studies with heterogeneous populations. We also obtained aggregate results co-ordinate to current definitions of clinical remission and low disease activity by reanalyses of individual patient data past study sponsors.

The systematic review formed office of a wellness technology assessment of biological medicines in rheumatoid arthritis conducted by the German health technology assessment agency, the Institute for Quality and Efficiency in Health Care (IQWiG). The full report (in German) and protocol are bachelor on the IQWiG website.13 IQWiG's methodological approach for systematic reviews is described in its methods paper.xiv

Methods

Search strategy and written report selection

Our systematic review was an update and extension of a previous systematic review published in 2013.xv Information retrieval was based on the previous review. Nosotros conducted a bibliographic search for relevant primary studies and secondary publications (systematic reviews and wellness technology cess reports). A list of the databases and search strategies is presented in supplement 1. The concluding search was conducted in February 2017.

The following boosted sources were searched to place farther studies: reference lists of iv electric current systematic reviews,16171819 clinical trial registries and study results databases, equally well equally the websites of the European Medicines Agency (EMA) and Us Food and Drug Administration (FDA). We too asked marketing authorisation holders of biological medicines canonical past the EMA and included in our systematic review to provide unpublished studies and additional unpublished data from published and unpublished studies. The biological medicines included and companies contacted are listed in supplement table ane.

As a prerequisite for the apply of unpublished information, IQWiG asked the marketing potency holders to sign an agreement requiring submission of a list of all sponsored published and unpublished studies investigating the biological medicine concerned, and of Espoused compliant documents (in general, the complete clinical study reports) on all relevant studies selected by IQWiG. This procedure was required to avoid bias due to selective provision of information. For all investigator initiated trials selected by IQWiG, sponsors were also asked to supply complete clinical study reports, if available.

To see both the methodological requirements of a network meta-assay and the current recommendations of rheumatoid arthritis societies, we aimed to include results from sufficiently similar patient populations and to use the most current definitions of rheumatoid arthritis outcomes. For this purpose, aggregate results of two types of reanalyses of private patient data from the studies included were requested from the study sponsors. Firstly, if only a subpopulation of the overall study population was relevant for the current systematic review, aggregate results from a reanalysis of characteristics of this subpopulation (eg, of the patients without pre-treatment with biological medicines) and results on all outcomes were requested. Secondly, for all studies or study subpopulations included, aggregate results from reanalyses of clinical remission (clinical affliction activity index (CDAI) ≤2.8) and low disease activity (CDAI ≤10) were requested, if not already available in the study documentation.

Nosotros included published and unpublished studies with the following characteristics: randomised clinical trials of adults (anile ≥xviii) with rheumatoid arthritis and a minimum study elapsing of 24 weeks comparison biological medicines with each other or with a potential mutual comparator for inclusion in a network meta-analysis. Studies were included if the biological medicines (approved until November 2016) were administered co-ordinate to regulatory approval (supplement table 1). For the analyses presented in this publication, we selected studies in patients treated with biological medicines in combination with methotrexate after methotrexate failure.

We included studies investigating at least ane of the post-obit predefined patient relevant outcomes: clinical remission, depression disease activity, hurting, concrete function, wellness related quality of life, fatigue, serious agin events, discontinuation due to agin events, infections, serious infections, and bloodshed. The availability of a full text document (eg, journal article or clinical study report) was required. No restrictions practical to the engagement of publication or to language. Non-English language or non-German citations had to include an English title or abstract indicating potential relevance for the review; in this case, the total text was obtained and translated.

Two reviewers independently screened titles and abstracts of the retrieved citations to identify potentially eligible publications. The full texts of these articles were independently evaluated by the same two reviewers. Principal publications on rheumatoid arthritis were identified and the full set of inclusion and exclusion criteria was then applied to identify eligible studies. All documents retrieved from not-bibliographic sources were also screened for eligibility or relevant information on studies by two reviewers. Disagreements were resolved past consensus.

Information extraction

The private steps of the data extraction and gamble-of-bias assessment procedures were ever conducted by ane person and checked past another; disagreements were resolved by consensus. The clinical study written report was the primary source for information extraction; if no report was available, nosotros used periodical manufactures, registry entries, and the corresponding results. Documents presenting reanalyses of written report information provided past study sponsors were additional sources. Study data were extracted by standardised tables routinely used past IQWiG and specifically adapted for this systematic review.

The following data was extracted from each included study: study characteristics (commendation, study design and duration, sample size, location, number of centres, time of written report carry, primary and secondary outcomes); intervention characteristics; characteristics of the planned population; baseline characteristics of patients included (general and disease specific characteristics, including previous and concomitant drug treatment); patient relevant outcomes and risk-of-bias items. After a period of public consultation on the preliminary protocol and report in March 2017 and July 2018, allowing four weeks to provide comments on the German language written report, the original protocol was amended. 1 major change affected the definition of low disease activity used in the review (from disease activity score (DAS) 28 <iii.2 to CDAI ≤10; the DAS 28 includes inflammatory parameters that could be influenced more by some biological medicines (eg, tocilizumab920) than by others, and could hamper a fair comparison of the furnishings of biological medicines on patient relevant outcomes).

The data extracted for this systematic review and the network meta-analysis is included in supplement 2. The complete datasets extracted from the individual studies are available in the full German language report.13

Quality assessment and gamble of bias

The hazard-of-bias cess followed IQWiG's methods 14 (see supplement tables 5-14 for assessment items). Risk of bias was assessed for all studies providing direct comparisons of relevant biological medicines. For whatever pairwise contrast contributing to an indirect comparison within the network, risk of bias was only assessed if two criteria were fulfilled: that the effect for the indirect comparison was statistically meaning and the pairwise contrast consisted of only one study. This arroyo was practical because, according to IQWiG's methods, a statistically significant effect for an indirect comparison in this constellation is relevant but if the single report shows a low run a risk of bias. If more than one written report with a loftier run a risk of bias contributes to the respective dissimilarity, the result is considered to be relevant, independently of the risk of bias.

The certainty of the conclusions from a network meta-analysis was determined by the number of studies informing the pairwise contrasts, inclusion of directly comparisons, homogeneity of the studies and consistency of direct and indirect comparisons, and the adventure of bias of the studies contributing to an effect (supplement two).

Data synthesis and statistical analysis

The prerequisite for conducting the network meta-analysis was an adequate structural quality of the study pool—that is, availability of a written report puddle meeting the assumptions of similarity, homogeneity, and consistency. In general, an indirect comparison allows estimation of an outcome between 2 treatments A and B in the absence of straight comparative trials if other trials comparison A or B with a mutual comparator C (intermediate comparator) are available. The validity of such an indirect estimate relies on the supposition that the bear witness obtained from the second group of trials is valid for the comparison of interest. This validity requires the assumption of similar study characteristics, such every bit the study pattern applied or the population investigated. If this assumption is non met, possible event modifiers could touch on the indirect approximate. A consequence of this supposition is that both the direct and the indirect estimations of the upshot of treatments A versus B produce comparable results. While the conceptual assumption is chosen "similarity" or "transitivity," the statistical consequence is called "consistency."

Homogeneity is also a consequence of the similarity assumption, just tin likewise generally be seen as a requirement in conventional meta-analyses.21222324 For the check-of-similarity assumptions, the following factors of the studies or study populations were considered: historic period, sex, disease severity, disease duration and pre-treatment of study population, intervention, concomitant medication, study elapsing, yr of study conduct, and the upshot measures considered. Homogeneity was causeless if no substantial heterogeneity occurred in the report pool for a given dissimilarity comprising ii or more than studies. Consistency was causeless if the estimates from an indirect comparison were confirmed past the estimates from a straight comparing in a airtight loop of the network. Study results were not pooled and analysed via the network meta-assay if whatever of the assumptions were rejected. If the bank check of homogeneity or consistency was not possible due to the network structure, the network meta-analysis was still conducted, but the certainty of the conclusion was downgraded.

We assessed heterogeneity using a test of interaction. Inconsistency was tested locally within each loop by the node splitting procedure.25 Details on the sensitivity analyses conducted in the example of heterogeneity or inconsistency (significance at the 0.05 level) are available in supplement 2.

Risk ratios and mean differences were the outcome measures used for binary and continuous outcomes, respectively. Run a risk ratios and their standard errors were normalised by taking logarithms of information from contingency tables. In the instance of zilch events in either treatment group, a factor of 0.v was added to each cell. Estimates of mean differences and their standard errors were extracted from the original scales used in the primary studies. In case of statistically significant furnishings, the concluding network meta-assay results of a continuous outcome analysis were supported by an additional analysis based on standardised furnishings by Hedges' k to assess the relevance of the effect. A relevant difference was assumed if the effect of the network meta-analysis based on standardised data was exterior the (−0.two to 0.ii) interval.14 All network meta-analyses were conducted within a frequentist setting using random furnishings models.26 We used the software bundle netmeta in R (supplement 2 includes the programming code). Each hypothesis of no difference between any two treatments was tested locally at the 0.05 level. Nosotros did not adjust for multiple testing. The resulting estimates from the network meta-assay were presented with 95% confidence intervals.

2 types of sensitivity analyses were performed for all analyses with the following goals. The first type of analyses identified sufficiently homogeneous and consistent study pools. The 2nd type of analyses checked whether the results were robust with regard to the similarity assumptions (that is, whether results inverse after removing studies including patients with different clinical characteristics that were accepted during the check of similarity; encounter supplement 2 for details).

We aimed to estimate differences betwixt biological medicines quantitatively. We refrained from ranking the network meta-analysis results, because our focus was on estimating actual treatment contrasts. In addition, each ranking method responds to a different question of interest and diverse methodological problems can hamper interpretation.2728 For example, ranking methods have been shown to be sensitive to network composition,29 do non reverberate a handling'due south effect size,30 and cannot always be accompanied by conviction or credible intervals.28 In contrast to the presentation of effect estimates and conviction or credible intervals, then far there is no established standard ranking should be used and, if and so, which method is to be preferred.

Patient and public involvement

Patients and the general public were involved in the full health technology assessment according to IQWiG'south methods, which are described in its methods paper.14 After the publication of the preliminary protocol and preliminary report, patients and the general public were asked to comment on the protocol and report. The comments and changes resulting from the comments are discussed in particular in dissever German language documents available on the IQWiG website.13 A major change from the preliminary to the final protocol was the adaption of the definitions for clinical remission and inclusion of the respective definitions for low disease activeness according to the current guidelines of the leading rheumatoid arthritis societies.

Results

Clarification of studies

Of 118 studies meeting the inclusion criteria for the health technology assessment (fig 1), 45 investigated biological medicines/methotrexate in the treatment of patients with rheumatoid arthritis after methotrexate failure (supplement table 2). Most studies used the 1987 ACR criteria for rheumatoid arthritis, while some likewise used the ACR/EULAR 2010 criteria. Supplement tables three and 4 show the characteristics of these studies; these data were used to check the similarity assumption.

Fig 1

Testify search and report choice. *Records excluded in screening of title, abstract, or full text (reasons for exclusion in title/abstract screening: violation of minimum inclusion criteria (that is, incorrect indication or intervention), not studying people, or no secondary publication (n=709); reasons for exclusion in full text screening: incorrect population (n=28), intervention (n=113), comparator (n=26) or study design (n=694); no full publication (n=96); wrong study duration (n=39) or language (n=five); and no patient relevant outcome (n=0)). †Infliximab/methotrexate versus placebo/methotrexate. ‡Ane study each for post-obit comparisons: adalimumab/methotrexate versus etanercept/methotrexate, tocilizumab/methotrexate versus etanercept/methotrexate. §One report each for following comparisons: adalimumab/methotrexate versus placebo/methotrexate, tocilizumab/methotrexate versus placebo/methotrexate. ¶Etanercept/methotrexate versus other synthetic illness modifying antirheumatic drugs. HTA=health engineering assessment; MTX=methotrexate

Download figure
Open in new tab
Download powerpoint

We saw bereft similarity in three studies (fig 1), and similarity could not exist assessed for ii studies considering of a lack of information on the relevant subpopulation. For 14 of the remaining twoscore studies, new information on subpopulations of the complete study populations was necessary to meet the similarity requirement for the network meta-assay. The main reasons were inclusion of patients pre-treated with biological medicines or inclusion of patients with varying concomitant drug treatment. New data for these subpopulations were available from the clinical study reports (ii studies), and from reanalysis of private patient data of the original study by the study sponsor (12 studies). Ii of the 40 studies coming together the similarity assumption were not linked to the network owing to the lack of a common comparator. Data from 38 sufficiently similar studies were thus bachelor for the network meta-assay.

Study characteristics

In the 38 studies, the hateful age in most of the study arms ranged between 50 and 60 years; 75-90% of patients were women. Disease duration was mostly between six and 12 years. Most studies included patient populations with severe rheumatoid arthritis and poor prognostic factors (eg, moderate to high disease activity or loftier swollen joint counts). The studies were initiated between 1997 and 2012.

During the assessment of similarity, uncertainties remained concerning affliction severity, which was either unknown or moderate (iv studies), too as an unknown or considerable proportion of patients (v-20%) pre-treated with biological medicines (iii studies). These uncertainties were investigated in 2 separate sensitivity analyses. For one study with missing information on illness severity and two studies on pre-handling with biological medicines, we did an additional sensitivity assay to investigate uncertainties caused by a lack of information. Supplement 2 provides details on the conduct and results of the sensitivity analyses (methods section and supplement tables xvi-19).

The 38 studies investigated 8 different biological medicines in combination with methotrexate. Only two studies reported a straight comparison of biological medicines (abatacept/methotrexate v adalimumab/methotrexate, and adalimumab/methotrexate v certolizumab pegol/methotrexate). All other studies compared a biological medicine/methotrexate with placebo/methotrexate: abatacept (n=six), adalimumab (due north=8), anakinra (due north=3), certolizumab pegol (n=iv), etanercept (n=3), golimumab (n=3), infliximab (due north=2), and tocilizumab (n=7).

Most randomised clinical trials (34 of 38) were double blinded and lasted vi to 12 months; in contrast, both directly comparisons and one placebo controlled study lasted two and 3 years, respectively (supplement table 3).

Network characteristics

Of 38 studies included in the network meta-analysis, analyses based on the prioritised CDAI definitions of clinical remission (CDAI ≤two.viii) or low affliction activity (CDAI ≤10) were available for four studies, and were provided subsequently reanalysis of individual patient data by the report sponsors for 30 studies. The following presentation of data are based on these reanalyses, where applicable. The remaining four studies without relevant data were thus excluded from the network meta-analysis for these outcomes.

The number of studies with bachelor data per effect ranged between 19 and 35 (supplement table 15). For all outcomes, most studies reported data subsequently 24 or 30 weeks. For some outcomes, data were as well (or only) available afterward 52 weeks. For all outcomes, information subsequently 24 and xxx weeks were considered if bachelor, because at these points fewer treatment adjustments or study discontinuations had occurred than later on on in the studies (in the event of lack of efficacy, 12 of 38 studies recommended handling switching and 26 of 38 studies recommended written report discontinuation). If only data after 52 weeks were bachelor, these were included in the network meta-analysis.

Considering merely two direct comparisons were available, the cess of consistency was simply feasible for the closed loops between abatacept/methotrexate, adalimumab/methotrexate, certolizumab pegol/methotrexate, and placebo/methotrexate. Supplement tables 16 and 17 bear witness the results for the checks of the homogeneity and consistency assumptions. Overall, the networks were mainly built from placebo controlled studies (fig 2 and supplement figures i and 2). All statistically significant and clinically relevant effects (defined every bit standardised effects by Hedges' k outside the (−0.2 to 0.2) interval for continuous data) from this network meta-analysis did non include data from directly comparisons. Therefore, the certainty of the conclusions on the advantages or disadvantages of one biological medicine compared with another was low for all outcomes.

Fig 2

Network plots of treatment comparisons for clinical remission, low affliction activity, serious agin events, infections, pain, and physical function in patients with rheumatoid arthritis. Network plots include the number of trials and the number of included patients for each comparison. CDAI=clinical disease action index; HAQ-DI=health cess questionnaire-disability index; MTX=methotrexate; n=number of included patients; VAS=visual analogue scale

Download effigy
Open in new tab
Download powerpoint

For each study outcome, we did homogeneity and consistency analyses also every bit sensitivity analyses investigating uncertainties for similarity assumptions to build the final network (supplement ii). Complete results from the network meta-analysis for each issue are presented in supplement tables xx to 23. Tabular array 1 and table 2 summarise the statistically pregnant and clinically relevant furnishings observed in the network meta-analysis.

Tabular array one

Statistically significant results representing added do good of biological medicines/methotrexate combinations for rheumatoid arthritis, from network meta-analyses comparing combinations

Table 2

Statistically significant results representing increased harm of biological medicine/methotrexate combinations for rheumatoid arthritis, from network meta-analyses comparison combinations

Comparative effects of biological medicines

Results for clinical remission (CDAI ≤ii.eight) were available from 34 studies covering 8 biological medicines. The terminal network afterwards investigating assumptions for network meta-analysis (fig two) included eight biological medicines (34 studies with ten 869 patients). Statistically meaning issue estimates from the network meta-analysis are presented in table 1. Statistically significant advantages were found for adalimumab, certolizumab pegol, and golimumab versus anakinra (table 1).

Results for low disease activeness (CDAI ≤10) were available from 33 studies roofing viii biological medicines. The final network after investigating assumptions for network meta-assay (fig two) included eight biological medicines (27 studies with 8198 patients). Statistically significant advantages were constitute for abatacept, adalimumab, infliximab, and tocilizumab versus anakinra (table one).

Results for pain (measured via a visual analogue scale) were bachelor from thirty studies roofing seven biological medicines. The terminal network after investigating assumptions for network meta-analysis (fig 2) covered all biological medicines apart from certolizumab pegol/methotrexate and golimumab/methotrexate (12 studies with 3931 patients). Statistically significant and clinically relevant advantages (upper limit of 95% confidence interval of standardised treatment effect <−0.two Hedges' k) were found for abatacept and tocilizumab versus anakinra (table i).

Results for physical function (measured via the Health Cess Questionnaire31) were available from 33 studies roofing eight biological medicines. The final network subsequently investigating assumptions for network meta-assay (fig ii) included eight biological medicines (29 studies with 9247 patients). No statistically significant and clinically relevant differences were seen between the biological medicines in the network (supplement table 21).

Results for serious adverse events were available from 34 studies covering 8 biological medicines. The last network after investigating assumptions for network meta-analysis (fig ii) included eight biological medicines (31 studies with 9934 patients). A statistically meaning disadvantage was constitute for certolizumab pegol versus abatacept, adalimumab, anakinra, etanercept, and infliximab (table two).

Results for infections were bachelor from 35 studies roofing eight biological medicines. The final network afterward investigating assumptions for network meta-analysis (fig 2) included eight biological medicines (31 studies with 10 036 patients). A statistically significant disadvantage was found for certolizumab pegol versus abatacept, anakinra, etanercept, golimumab, and tocilizumab (tabular array 2).

Other outcomes

The networks of further outcomes are presented in supplement figures 1 and 2. A statistically significant and clinically relevant advantage was institute for golimumab versus anakinra with regard to health related quality of life (table one). Statistically significant disadvantages were also constitute for anakinra and certolizumab pegol versus several other biological medicines with regard to discontinuation due to adverse events and serious infections, respectively; tocilizumab versus abatacept with regard to discontinuation due to adverse events; and golimumab and tocilizumab versus infliximab with regard to serious infections (table 2). Nosotros found no statistically significant differences for fatigue and mortality (supplement tables 22 and 23).

Uncertainty of furnishings

The network meta-analysis identified only a limited number of statistically significant and clinically relevant effects (table one and table two). However, almost 30% of the not-pregnant effects (74 of 238 furnishings) had broad 95% confidence intervals of risk ratios (including 0.five and 2.0) or of mean differences (including x% of the scale range; supplement tables 20 to 23). These wide confidence intervals underline the uncertainty of the results and could take been caused past the fact that the network meta-analysis included but a few direct comparisons and that several indirect comparisons were based on a express number of studies.

On the other hand, wide 95% confidence intervals were observed in only five of 28 (eighteen%) comparisons for low affliction activity, in three of 28 (11%) for serious adverse events, and in none for infections. The results for these key outcomes were thus less uncertain.

Discussion

Primary findings

Overall, our network meta-assay showed only few statistically significant differences in benefits and harms between the biological medicines included. Anakinra/methotrexate showed less benefit than whatsoever other biological medicine (except for etanercept/methotrexate) with regard to clinical remission or depression illness action, and certolizumab pegol/methotrexate showed more harm than whatever other biological medicine with regard to serious agin events or infections. Furthermore, golimumab/methotrexate and tocilizumab/methotrexate showed more infections than infliximab/methotrexate.

Confidence intervals were very broad for some outcomes with low result numbers (eg, remission and bloodshed), potentially implying unidentified differences between biological medicines. However, wide confidence intervals were less prominent in the key outcomes of low disease activity, serious adverse events, and infections, which had college event numbers. In our opinion, these results propose that overall differences between biological medicines are indeed only minor.

In the past few decades, the handling goal for rheumatoid arthritis has changed substantially, from slowing down progression to depression affliction action and ultimately to clinical remission. Furthermore, the definition of clinical remission is now stricter. The remission benchmark of the DAS 28 allowing for a higher number of swollen joints was replaced by more stringent criteria, of which the CDAI remission criterion seems to exist the about useful tool for clinical decision making. In addition, compared with the DAS 28 definition or other response criteria such as the ACR50, the new definitions for low affliction activity (such as CDAI ≤10) are also stricter, assuasive for less affliction burden than the older definitions. We therefore used the updated definitions in our network meta-assay and asked report sponsors to reanalyse the study information appropriately.

In an era of treat-to-target strategies and novel therapeutic drugs such as biological medicines, clinical remission of rheumatoid arthritis remains the main treatment goal, even afterwards methotrexate failure. Except for anakinra, we saw no proof of differences in clinical remission between the other biological medicines. This result is reflected past the current rheumatoid arthritis guidelines of the ACR (2015) and the EULAR (2019). Except for anakinra, the lack of proven added benefit of one biological medicine combined with methotrexate over some other means that all combinations are similarly suitable treatment choices. The choice of a specific biological medicine should therefore be based on relevant patient characteristics, including comorbidities (if possible) and patients' preferences. In improver, the cost of treatment should be considered, and becomes even more important equally an increasing number of biosimilars becomes available.ix

This network meta-assay found higher rates of serious adverse events and infections for certolizumab pegol/methotrexate than for all other biological medicines. In contrast, a recently published report from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis found a lower charge per unit of serious infections for certolizumab pegol than for all other biological medicines (hazard ratio 0.75, 95% confidence interval 0.58 to 0.97).32 Both methods generating these results (that is, indirect comparisons via network meta-analyses on the one hand and adjusted analyses from observational data on the other) inherently subtract the certainty of conclusions. In the consequence of contradicting results, the open question can merely be solved by information from a more than reliable report design (that is, a randomised clinical trial). Given the large patient numbers required, preferably a large and uncomplicated (registry based) randomised trial3334 might be the solution. In the case of serious adverse events and infections in patients receiving certolizumab pegol, this report is even more important, because certolizumab pegol is one of the few biological medicines approved for pregnant women.

Strengths and limitations of this written report

Ensuring the similarity and homogeneity of the studies for a network meta-analysis frequently is hampered by the fact that periodical publications, which still represent the main data source for many systematic reviews, provide insufficient data on patient and study characteristics.3536 This problem was negligible for our network meta-analysis because we had access to clinical study reports for twoscore of the 45 studies considered. These comprehensive documents, which include study protocols and complete data on all items collected in a report, are specially helpful when a detailed clarification of studies and patients is required.

In this network meta-analysis, for the first time reanalyses of many studies were able to make relevant patient subpopulations from studies with broader inclusion criteria available for a network meta-analysis. We were therefore able to include 12 (of a full of 40) studies that would otherwise have been excluded from our study pool owing to a lack of similarity. This finding underlines the value of individual patient data for secondary analyses of studies and supports the phone call for broad availability of anonymised private patient information to maximise clinical research findings.3738

To our knowledge, this network meta-analysis is the first to focus on similar, upward-to-date consequence information on clinical remission and low illness activity (based on the CDAI). Fifty-fifty more than recent analyses used the DAS 28 and ACR response criteria,173940 even though they are no longer recommended.9 The changes in definitions of clinical remission and low disease activity also resulted in different outcome measures in the studies included in our network meta-analysis. While newer studies used the definitions from ACR and EULAR,10 data analysed co-ordinate to these definitions were not available in older studies, which would have prevented the inclusion of these of import outcomes in our network meta-assay for a big proportion of studies. The switch to the CDAI was but possible considering study sponsors reanalysed the respective low illness activity and clinical remission outcomes from the individual patient data (low illness activeness: 26 of 27 studies; remission: 30 of 34 studies).

Overall, the reanalysis based on private patient data from primary studies is one of the major strengths of our network meta-assay. A further strength is the identification and inclusion of studies that fulfilled the predefined criteria for similarity, as described and discussed below.

This network meta-analysis likewise had several limitations. For case, one biological medicine and two Janus kinase inhibitors approved recently (sarilumab, tofacitinib, and baricitinib) were not included. However, the private assessment of these new drugs by IQWiG also only found minor differences compared with established biological medicines in patients subsequently methotrexate failure.4142434445 An update of the present network meta-analysis should notwithstanding include these drugs.

Handling strategies have changed over the by years. Nowadays, the diagnosis and treatment of rheumatoid arthritis start at a much earlier phase. In addition, the treat-to-target paradigm has resulted in the before escalation of treatment. Furthermore, our findings probably do not apply to patients with moderate rheumatoid arthritis, considering the network meta-analysis largely included patients with high illness action.

Comparison with other studies

Several network meta-analyses of biological medicines in rheumatoid arthritis are available, including two contempo Cochrane reviews.173940 A major difference between these network meta-analyses and our analysis seems to exist the arroyo for testing the assumptions for the network meta-analyses, specifically similarity and homogeneity. For instance, while we extensively analysed patient characteristics and treatments to identify similar studies before inclusion in the network meta-analysis, Singh et al17 did not report an assessment of similarity and included more than heterogeneous written report pools. Furthermore, they did not report tests for homogeneity in the pairwise meta-analyses included in the networks. Although they performed sensitivity analyses for several factors, overall information technology remains unclear to what extent the assumptions for a network meta-analysis were met in their analyses. Hazlewood et al3940 reported more detailed information on study and patient characteristics and reported tests for homogeneity in pairwise meta-analyses. Even so, similar Singh et al, the authors did not report measures or quantitative results to assess or exam the network meta-analysis assumptions (such as P values for heterogeneity tests or measures to estimate inconsistency). Thus, it also remains unclear to what extent the assumptions for network meta-analysis were met in their analyses.

Unanswered questions and time to come research

The PRISMA extension statement for reporting systematics reviews containing network meta-analyses includes a clear requirement (in the checklist) simply with regard to the bank check of consistency.21 The information on the check of the similarity and homogeneity assumptions is less precise and, while the elaboration document of the statement suggests reporting information on study characteristics and heterogeneity tests, it does not seem to require that these assumptions are met every bit a prerequisite for a network meta-analysis. Since the network meta-analysis concept relies on the similarity and homogeneity assumptions,46 farther discussion is needed on reporting requirements and on approaches to ensure that these assumptions are met.

Owing to a very low number of direct comparisons in our networks, nosotros were not able to assess the consistency of directly and indirect upshot estimates for well-nigh of the contrasts. Therefore, we could only derive conclusions of low certainty. This finding underlines the fact that a network meta-analysis cannot compensate a lack of directly comparisons; a sufficient number of direct comparisons is required to fully exploit the potential of this blazon of analysis.

The comprehensive information retrieval conducted for this network meta-analysis identified a large number of studies. However, the proportion of direct comparisons and long term studies was very depression. Given the fact that several biological medicines have been available for about 20 years and that rheumatoid arthritis affects many patients, the authorisation of short term placebo controlled studies indicates a failure of report planning in this treatment indication. This problem was already described several years ago and has patently not been solved.47

Conclusions and policy implications

For patients with rheumatoid arthritis after methotrexate failure, our network meta-assay using rigorous methods showed overall small-scale differences in benefits and harms between biological medicines in combination with methotrexate. Yet, the analysis was hampered by a lack of long term direct comparisons. The substantial information proceeds accomplished by the reanalysis of individual patient data calls for the routine availability of private patient data.

What is already known on this topic

Previous meta-analyses have shown that nearly biological medicines combined with methotrexate are more than constructive at controlling disease activity in rheumatoid arthritis than treatment with methotrexate alone
Nonetheless, the comparative benefits and harms of the biological medicines are nevertheless nether discussion
Previous network meta-analyses on this topic have included heterogeneous patient populations and older definitions of key outcomes such as clinical remission and low affliction action, making the results of these analyses inconclusive

What this study adds

Inclusion of data from clinical report reports and reanalyses from individual patient data has enabled the inclusion of like patient populations and unknown results on current definitions of clinical remission and low disease activity and other endpoints in this network meta-assay
This systematic review and network meta-assay indicates minor differences between biological medicines for the treatment of rheumatoid arthritis, when combined with methotrexate afterwards methotrexate failure
This data could be important for clinical practice, considering the changes in treatment strategies for rheumatoid arthritis and the increasing number of biosimilar biological medicines available

Acknowledgments

We thank Corinna Kiefer for supporting statistical analyses and Natalie McGauran for editorial support; and the written report sponsors (supplement table 1) for providing reanalyses of individual patient data for the studies included in the network meta-analysis.

Footnotes

Contributors: BW, KB, KJ, CS, DK, and BR conceived and designed the study. KJ, KB, CS, KH, DK, BR, and BW analysed and interpreted the data. KJ, KB, BW, and CS drafted the outset version of the manuscript. KJ, KB, and HH screened studies for inclusion and KJ, HH, PK, and MFK extracted information. CS and KH checked information extraction and performed statistical analyses. All authors canonical the final typhoon of the manuscript. BW is the guarantor. The corresponding author attests that all listed authors see authorship criteria and that no others meeting the criteria accept been omitted.
Funding: This work was supported by the Found for Quality and Efficiency in Health Intendance. No external financial support was received. Viii of the 10 authors are IQWiG employees and (as the remaining two authors) were involved in the study design and in the collection, assay, and interpretation of data besides every bit in the writing of the report and the decision to submit the commodity for publication.
Competing interests: All authors take completed the ICMJE compatible disclosure class at www.icmje.org/coi_disclosure.pdf and declare: support from the Institute for Quality and Efficiency in Wellness Care for the submitted work; no financial relationships with whatever organisations that might have an interest in the submitted piece of work in the previous three years; no other relationships or activities that could appear to take influenced the submitted work.
Upstanding approval: Not required.
Data sharing: Additional data are available in the full (German language language) study on the IQWiG website.13
The manuscript's guarantor (BW) affirms that the manuscript is an honest, authentic, and transparent account of the review being reported; that no important aspects accept been omitted; and that whatsoever discrepancies from the original protocol take been explained.
Dissemination to participants and related patient and public communities: The results of our study have been made available to the patient representatives who are office of the conclusion making torso for which the original wellness technology assessment report was prepared and to patients and the public by publication of the wellness applied science cess report on IQWiG'due south website. An hands understandable summary will be made available to patients and the public on IQWiG'south patient information website (English version: https://world wide web.informedhealth.org/).

View Abstract

hardestyopeance73.blogspot.com

Source: https://www.bmj.com/content/370/bmj.m2288